Clinical Trial Update: NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial of neoadjuvant gemcitabine/oxaliplatin followed by adjuvant gemcitabine in resectable pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Eloxatin (oxaliplatin)
• Gemzar (gemcitabine)

Snippet

Sponsor: Institut Paoli-Calmettes | Conditions: Pancreas Cancer | Phase 3 | Status: COMPLETED